Cargando…
Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis
BACKGROUND: To evaluate the immune checkpoint inhibitors (CPI) for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC). MATERIALS AND METHODS: A meta‐analysis was conducted, and the efficacy and safety of CPI were assessed. RESULTS: A total of 13 studies with 980 patient...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838749/ https://www.ncbi.nlm.nih.gov/pubmed/36329570 http://dx.doi.org/10.1111/srt.13229 |
_version_ | 1784869345258635264 |
---|---|
author | Zhang, Haoran Zhong, Ai Chen, Junjie |
author_facet | Zhang, Haoran Zhong, Ai Chen, Junjie |
author_sort | Zhang, Haoran |
collection | PubMed |
description | BACKGROUND: To evaluate the immune checkpoint inhibitors (CPI) for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC). MATERIALS AND METHODS: A meta‐analysis was conducted, and the efficacy and safety of CPI were assessed. RESULTS: A total of 13 studies with 980 patients were included. The pooled objective response rate (ORR) and disease control rate were 47.2% and 64.4%, separately. In addition, patients with primary tumor located in head and neck (odds ratio [OR]: 0.374, 95% confidence interval [CI]: 0.219–0.640, p < 0.001) and positive expression of programmed death ligand 1 (OR: 0.364, 95% CI: 0.158–0.842, P = 0.018) had superior ORR during CPI treatment. The incidence of progression free survival at 6 and 12 months was 59.3% and 52.8%, and 80.6% and 76.4% for overall survival. As for safety, the overall incidence of adverse events with all grades and 3–4 grade was 76.9% and 20.2%. CONCLUSIONS: Our systematic review confirmed the satisfying efficacy and acceptable toxicity of CPI for advanced CSCC. |
format | Online Article Text |
id | pubmed-9838749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98387492023-04-13 Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis Zhang, Haoran Zhong, Ai Chen, Junjie Skin Res Technol Original Articles BACKGROUND: To evaluate the immune checkpoint inhibitors (CPI) for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC). MATERIALS AND METHODS: A meta‐analysis was conducted, and the efficacy and safety of CPI were assessed. RESULTS: A total of 13 studies with 980 patients were included. The pooled objective response rate (ORR) and disease control rate were 47.2% and 64.4%, separately. In addition, patients with primary tumor located in head and neck (odds ratio [OR]: 0.374, 95% confidence interval [CI]: 0.219–0.640, p < 0.001) and positive expression of programmed death ligand 1 (OR: 0.364, 95% CI: 0.158–0.842, P = 0.018) had superior ORR during CPI treatment. The incidence of progression free survival at 6 and 12 months was 59.3% and 52.8%, and 80.6% and 76.4% for overall survival. As for safety, the overall incidence of adverse events with all grades and 3–4 grade was 76.9% and 20.2%. CONCLUSIONS: Our systematic review confirmed the satisfying efficacy and acceptable toxicity of CPI for advanced CSCC. John Wiley and Sons Inc. 2022-11-03 /pmc/articles/PMC9838749/ /pubmed/36329570 http://dx.doi.org/10.1111/srt.13229 Text en © 2022 The Authors. Skin Research and Technology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Zhang, Haoran Zhong, Ai Chen, Junjie Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis |
title | Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis |
title_full | Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis |
title_fullStr | Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis |
title_full_unstemmed | Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis |
title_short | Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta‐analysis |
title_sort | immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: a systemic review and meta‐analysis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838749/ https://www.ncbi.nlm.nih.gov/pubmed/36329570 http://dx.doi.org/10.1111/srt.13229 |
work_keys_str_mv | AT zhanghaoran immunecheckpointinhibitorsinadvancedcutaneoussquamouscellcarcinomaasystemicreviewandmetaanalysis AT zhongai immunecheckpointinhibitorsinadvancedcutaneoussquamouscellcarcinomaasystemicreviewandmetaanalysis AT chenjunjie immunecheckpointinhibitorsinadvancedcutaneoussquamouscellcarcinomaasystemicreviewandmetaanalysis |